Retention rate

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on MSCI Inc. (NYSE: MSCI)

Retrieved on: 
Wednesday, January 17, 2024
Professional Services, Finance, Hand, Research, Executive Committee, Quarter, Risk, RiskMetrics, G&A, Audit committee, Friction, Climate, Pension, Growth, Textile, Record, Menai, Data management, Capital, CFO, ESG, Morgan Stanley, BlackRock, ETF, Analytics, Software, Congress, Disclosure, EFront, Doctor of Philosophy, Marketing, Retention rate, Thought, Physics, RCA, Outline, GAAP, Acquisition, Deutsch, SolarWinds, IShares, Weakness, Yoy, Vanguard, Bloomberg, Humboldt Hill, California, Adjustment, Interview, CPA, Fraud, SWI, Pressure, IPO, EPS, AUM, Cryptocurrency

MSCI, founded as Morgan Stanley Capital International, is a provider of decision support tools and solutions for the global investment community.

Key Points: 
  • MSCI, founded as Morgan Stanley Capital International, is a provider of decision support tools and solutions for the global investment community.
  • In addition, MSCI also faces additional strain from its clients – such as BlackRock – that are under pressures of their own.
  • Higher rates have caused total assets of AUM benchmarked to MSCI indices to decline almost double digits since 2021.
  • For example, Spruce Point observes that MSCI recently experienced year-over-year declines in its organic sales growth, Adjusted EBITDA margin and client Retention Rate metrics.

Seoul St. Mary's Hospital Found Red Ginseng Oil is Excellent for Improving Prostatic Hyperplasia

Retrieved on: 
Thursday, September 14, 2023
Korea Ginseng Corporation, Retention rate, Urine, BPH, KGC, International Prostate Symptom Score, Nocturia, Research, Multimedia, JUNG, Malignancy, Capsule, Professor, Patient, Hospital, Department of Urology, University of Virginia, Ageing, Benign prostatic hyperplasia, Dietary supplement, IPSS

SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.

Key Points: 
  • SEOUL, South Korea, Sept. 14, 2023 /PRNewswire/ -- Red ginseng oil has been found to be a safe and effective solution for improving prostatic hyperplasia for the first time.
  • Led by Professor Kim Sae Woong from the Department of Urology at Seoul St. Mary's Hospital, in collaboration with the Korea Ginseng Corporation (KGC), this research's results indicate that the intake of red ginseng oil extracted from JUNG KWAN JANG's RXGIN can safely and effectively improve prostatic hyperplasia.
  • It turns out that, compared to a mere 3.7% improvement in the control group, the red ginseng oil group experienced a significant 50.5% improvement in the red ginseng oil group in IPSS.
  • Professor Kim explained, "We found that red ginseng oil not only significantly improves the symptoms of BPH but also enhances dysfunction, which are the side effects of existing BPH(Benign prostatic hyperplasia) treatments."

Zuora Reports First Quarter Fiscal 2024 Results

Retrieved on: 
Wednesday, May 24, 2023
Technology, Payments, Finance, Fintech, Other Technology, Accounting, Professional Services, Software, Digital Cash Management, Digital Assets, Other Professional Services, Workforce, Insurance, Loss, Retention rate, Table, GAAP, Metric, Public expenditure, Conference call, Acquisition, ACV, Webcast, ARR, Growth, Conference, Bookkeeping, Bank, Pharmaceutical industry

(1) Non-GAAP net income per share was computed assuming 138.6 million and 140.2 million weighted-average shares outstanding for the second quarter and full fiscal year 2024, respectively.

Key Points: 
  • (1) Non-GAAP net income per share was computed assuming 138.6 million and 140.2 million weighted-average shares outstanding for the second quarter and full fiscal year 2024, respectively.
  • Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
  • A replay of the webcast will be available through May 22, 2024.
  • We believe these non-GAAP measures provide investors consistency and comparability with our past financial performance and facilitate period-to-period comparisons of our operating results.

Zuora Reports Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on: 
Wednesday, March 1, 2023
Software, Payments, Finance, Accounting, Professional Services, Technology, Fintech, Digital Cash Management, Digital Assets, Retention rate, Workforce, Marketing, Loss, ARR, Acquisition, Insurance, GAAP, Table, Net, Conference, Webcast, Metric, Growth, ACV, Conference call, Reinsurance, Pharmaceutical industry, Bookkeeping, Bank

Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

Key Points: 
  • Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
  • Additionally, free cash flow has not been reconciled to operating cash flows as it cannot be reasonably calculated or predicted at this time.
  • Webcast and Conference Call Information:
    Zuora will host a conference call for investors on March 1, 2023 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the company’s financial results and business highlights.
  • We believe these non-GAAP measures provide investors consistency and comparability with our past financial performance and facilitate period-to-period comparisons of our operating results.

DigiCom Doubles Revenue and Grows Headcount by 200% Year-over-Year in 2022

Retrieved on: 
Tuesday, January 10, 2023
Communication, Software, Advertising, Retention rate, MysteryVibe, Acquisition, Growth, Data analysis, Marketing, Sales, Alkem Laboratories

NEW YORK, Jan. 10, 2023 /PRNewswire-PRWeb/ -- DigiCom, a leading growth and acquisition marketing agency, today announced that they have doubled their revenue year-over-year due to significant increases in managed media budgets, client retention, and overall client volume. DigiCom's customized programs are designed to position emerging direct to consumer companies for growth by helping partners develop a robust growth strategy and provide services to set up all growth channels, generate creatives for advertising, manage all online marketing campaigns, and build a foundation for insightful data analysis.

Key Points: 
  • In 2022, DigiCom expanded service offerings to drive customer acquisition through paid media across over 30 platforms, in-house creative development, influencer management, sponsored content, email marketing, and in-house CRO (conversion rate optimization) and website development.
  • To scale with expansion, DigiCom, based in New York City, added an international office in India, and grew its overall headcount by 200%.
  • In 2022, DigiCom added new national logos to its client partners including OneSkin, UmamiCart, Alkeme, and MysteryVibe.
  • To support partner growth, DigiCom is segmenting all new service offerings into 2023 and spinning them off with designated heads of business.

Global Cancer Pain Market Report 2022: Industry set to Grow by 5.71% Annually Through 2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 12, 2022
Pharmaceutical, Health, Oncology, CAGR, Cancer pain, Sleep, Revenue, Transitive dependency, Government budget balance, Population, Retention rate, USD, Research report, Region, Dietary supplement

The "Cancer Pain Market Analysis by Disease Indication, by Drug Type, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Pain Market Analysis by Disease Indication, by Drug Type, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The cancer pain market size is estimated to be USD 6,599.12 million in 2021 and is expected to witness a CAGR of 5.71% during the forecast period 2022-2029.
  • This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease indication and drug type from 2021 to 2029.
  • Segmentation: Cancer Pain Market Report 2021-2029Disease Indication (Revenue, USD Million)

Fresenius Kabi Expands Ready-to-Administer Portfolio with Glycopyrrolate Injection, USP Simplist® Prefilled Syringe

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Health, Pharmaceutical, Nursing, Medical Supplies, Use, Ulcerative colitis, Intubation, Multimedia, Intraocular pressure, Tachycardia, Myasthenia gravis, LinkedIn, Palpitations, LLC, Hyperthyroidism, Glaucoma, Spasticity, Diarrhea, Heart rate, Photophobia, Coronary artery disease, Exertion, Heart, Somnolence, Pupil, Bradycardia, Arrhythmia, Xerostomia, Nursing, Plasma protein binding, Retention rate, Peptic ulcer disease, Pharmacology, CEO, USP, Colostomy, Bowel obstruction, Acute hemorrhagic conjunctivitis, Cholinergic, Wax, Pharmacy, Mydriasis, FDA, Science, Brain damage, Ileostomy, Potassium chloride, Pharmacist, Anesthesia, RTA, Bromide, Blurred Vision, Gastrointestinal tract, Patient, Hypertension, Obstructive uropathy, Fresenius (company), Syringe, The I.V. Stalin White Sea – Baltic Sea Canal, Toxic megacolon, Pharmaceutical industry, Borosilicate glass, Medicine, Generic drug

Fresenius Kabi announced today the immediate availability in the U.S. of Glycopyrrolate Injection, USP in 0.6 mg per 3 mL Simplist ready-to-administer prefilled syringes .

Key Points: 
  • Fresenius Kabi announced today the immediate availability in the U.S. of Glycopyrrolate Injection, USP in 0.6 mg per 3 mL Simplist ready-to-administer prefilled syringes .
  • View the full release here: https://www.businesswire.com/news/home/20220725005542/en/
    Fresenius Kabi Glycopyrrolate Injection, USP 0.6 mg per 3 mL Simplist ready-to-administer prefilled syringe (Photo: Business Wire)
    Fresenius Kabi Simplist Glycopyrrolate Injection, USP is the most recent manufacturer-prepared product available in the companys proprietary, ready-to-administer portfolio of Simplist prefilled syringes, which reduce the amount of time nurses spend preparing doses and documenting waste.1
    Fresenius Kabi is focused on helping reduce clinician burden by expanding our ready-to-administer offerings, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Were pleased that our Simplist prefilled syringe portfolio now includes Glycopyrrolate Injection, USP, which will minimize preparation complexity to streamline workflows and help support patient safety in the U.S.
    Fresenius Kabi Glycopyrrolate Injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 mL prefilled syringe for reversal of neuromuscular blockade.
  • Fresenius Kabi Simplist Glycopyrrolate Injection, USP is formulated, filled and packaged in the U.S., and is the newest example of the companys commitment to investing More in America .

Trident University International DBA Graduate Presents Research on Workplace Retention in the Military

Retrieved on: 
Wednesday, November 3, 2021
Maguire, Retention rate, Organizational structure, Military History Matters, Research, Transition, Higher Learning Commission, Ethnic minorities in the U.S. armed forces during World War II, Human services, Higher, College, Motivation, Publishing, Impact, Air force, Faculty, Business school, Trident University International, Special operations, HelloFresh, Business administration, Trial balance, Doctor, Hotel manager, CORE, School of education, Confidentiality, American, DSP, Eastern Michigan University College of Health and Human Services, Education, Job satisfaction, DBA, Student, Management, Retail, Medicine

"The results of my research suggest that there are multiple variables that had a direct or inverse relationship with retention," explains Dr. McGuire.

Key Points: 
  • "The results of my research suggest that there are multiple variables that had a direct or inverse relationship with retention," explains Dr. McGuire.
  • With his DBA now completed, Dr. McGuire is already considering the next steps for his research.
  • Founded in 1998, Trident University International is a member of the American InterContinental University System, which is accredited by the Higher Learning Commission (hlcommission.org).
  • Trident has over 32,000 alumni, of which more than 27,000 have a military affiliation, and has received acknowledgements from Washington Monthly, Military Times, and Military Advanced Education & Transition for their dedication to student success.

DGAP-News: TeamViewer AG: TeamViewer confirms preliminary Q3/9M results with healthy and profitable billings growth

Retrieved on: 
Wednesday, November 3, 2021
Cloud, EBITDA, Retention rate, Contract, Industry, APAC, AR, Rate, SAP, Partnership, NRR, Google Cloud, EUR, Capital market, Net, TeamViewer (company), Software, Depression, Investment, EMEA, Growth, TeamViewer, LTM, Solution, Augmented reality, GDPR, COVID, Front line, Coffee, Mobile phone

While billings growth and profit remain very attractive, we are not satisfied with those results.

Key Points: 
  • While billings growth and profit remain very attractive, we are not satisfied with those results.
  • The improvement of our Net Retention Rate and the increase of the average billings per customer reflect a positive momentum.
  • The company grew third quarter billings by 18% (18 cc 1 ) to EUR 125.8m compared to the same period last year and after 15% billings growth in Q2 2021.
  • TeamViewer's most mature market, EMEA, showed strong third quarter billings growth of 25% (24% cc), billings in the Americas grew by 17% (17% cc).

Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring® Treatment for Enlarged Prostate Symptoms

Retrieved on: 
Monday, October 4, 2021
Sleep, Clinical trial, Man, IPSS, American Urological Association, Collection, Urination, BPH, Sale, Patient, Frustration, Professor, International Prostate Symptom Score, Urology, Urethra, Principal, Soldier Meadows hot spring system, Prostate, SAN, Retention rate, University of Texas Southwestern Medical Center, Safety, Quality of life, Spring system, GLOBE, Department, Medical imaging, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc. , a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE pivotal clinical trial to evaluate its Spring System.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc. , a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE pivotal clinical trial to evaluate its Spring System.
  • The symptoms associated with enlarged prostate have a substantial impact on patients quality of life, said Dr. Roehrborn.
  • I am encouraged by the potential for the Spring treatment to improve the patient experience and am proud to be part of this rigorous clinical trial program.
  • The BREEZE trial is a prospective, multicenter, controlled study in patients with lower urinary tract symptoms due to enlarged prostate.